Scarica l'app Stockscreener
2.42
1.22%
-0.03
Dopo l'orario di chiusura:
2.46
0.04
+1.65%
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
EV Market: Is ALX Oncology Holdings Inc a stock for growth or value investorsEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ALX Oncology (ALXO) Expected to Announce Earnings on Friday - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is ALX Oncology Holdings Inc. stock dividend yield sustainable2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments - RTTNews
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - Investing News Network
Analyst Upgrade: Does ALX Oncology Holdings Inc stock have upside surprise potential2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - Bitget
Why ALX Oncology Holdings Inc. stock could outperform in 2025Trade Signal Summary & Verified Momentum Stock Alerts - mfd.ru
Growth Recap: Is Expeditors International of Washington Inc stock trending bullishJuly 2025 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Does ALX Oncology Holdings Inc. have strong EBITDA marginsWeekly Trade Review & Accurate Intraday Trading Signals - mfd.ru
Will ALX Oncology Holdings Inc. outperform tech stocksGDP Growth & Expert Verified Stock Movement Alerts - mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearWeekly Profit Summary & Fast Moving Stock Trade Plans - mfd.ru
Will ALX Oncology Holdings Inc. stock pay special dividends2025 EndofYear Setup & Safe Investment Capital Preservation Plans - mfd.ru
Will ALX Oncology Holdings Inc. stock benefit from upcoming earnings reports2025 Risk Factors & Weekly High Momentum Picks - mfd.ru
Will ALX Oncology Holdings Inc. stock hit new highs in YEARQuarterly Trade Review & Breakout Confirmation Alerts - mfd.ru
Meme Stocks: Can ALX Oncology Holdings Inc reach all time highs this yearJuly 2025 Spike Watch & Reliable Breakout Forecasts - baoquankhu1.vn
Is ALX Oncology Holdings Inc. a stock for growth or value investorsPortfolio Performance Summary & Stepwise Trade Signal Implementation - mfd.ru
ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN
3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance
Is ALX Oncology Holdings Inc. stock forming a triangle patternJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Institutional Investor Builds Significant Stake in ALX Oncology - AD HOC NEWS
ALXO: Analyst Raises Price Target to $4.00, Maintains Overweight Rating | ALXO Stock News - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology (ALXO) Rises on Significant Share Purchase by venBi - GuruFocus
ALX Oncology (NASDAQ:ALXO) Director Corey Goodman Acquires 3,184,713 Shares - MarketBeat
Wilson Sonsini Advises ALX Oncology on Public Offering - Wilson Sonsini
CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants - Nasdaq
ALX Oncology prices $150 million stock offering at $1.57 per share - Investing.com Nigeria
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer - Investing News Network
ALX Oncology reports CD47 biomarker findings in breast cancer trial By Investing.com - Investing.com Nigeria
ALXO Unveils Promising Data from Evorpacept Trial in Breast Canc - GuruFocus
ALX Oncology announces major underwritten public equity offering - TipRanks
ALX Oncology Announces Pricing of Underwritten Offering - The Manila Times
ALX Oncology reports CD47 biomarker findings in breast cancer trial - Investing.com
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - The Manila Times
ALX Oncology Holdings Inc Announces New Clinical Trial Data - TradingView
What is ALX Oncology Holdings Inc.’s book value per shareTrade Exit Report & Daily Chart Pattern Signals - mfd.ru
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):